Patent: 7,507,704
✉ Email this page to a colleague
Summary for Patent: 7,507,704
| Title: | Receptor modulated cancer protocols |
| Abstract: | The present invention discloses that prior art protocols that administer HER receptor blockers concurrently with phase specific cytotoxic chemotherapeutics result in antagonistic function that prevents subsequent administrations of phase specific cytotoxic from functioning. The present invention provides protocols that allow the two classes of drugs to function synergistically. Moreover, the present invention also identifies that gompertzian tumor growth results in heterogeneity of cell cycle times in a tumor and that chemotherapeutic depopulation of the tumor results in accelerating cell cycle times, both of which preclude synchronicity of successive administrations of S-Phase cytotoxics relative to the progression of the S-Phase in the cancer cell population under prior art protocols. Present invention provides novel \"synchronous\" protocols for S-Phase cytotoxics, using HER blockers, to overcome this problem. Present invention also discloses how to integrate protocols of U.S. Pat. No. 6,486,146 for HER+ cancers that are also endocrine dependent. |
| Inventor(s): | Zamoyski; Mark (San Jose, CA) |
| Assignee: | |
| Application Number: | 11/809,264 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,507,704
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2022-11-15 |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2022-11-15 |
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2022-11-15 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
